Physician profile
Simi Suri
NPI 1578715355
$607.26
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $119 · 2021: $48.61 · 2022: $31.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $292.09 | 2019 | |
| Therapeuticsmd, INC. | $82.29 | 2019-2020 | |
| Avion Pharmaceuticals | $57.68 | 2020 | |
| Abbvie INC. | $44.66 | 2019-2021 | |
| Organon LLC | $31.51 | 2022 | |
| Daiichi Sankyo INC. | $23.30 | 2021 | |
| Evofem Biosciences, INC. | $22.34 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.07 | 2019 | |
| Roche Diagnostics Corporation | $20.52 | 2019 | |
| Millicent US INC | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simi Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.